Press Releases April 29, 2026 10:00 AM

SkinHealth Systems to Report First Quarter 2026 Financial Results on May 7, 2026

SkinHealth Systems schedules Q1 2026 financial results release and investor call for May 7, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SKIN

SkinHealth Systems Inc., a leading global medical aesthetics company known for its Hydrafacial treatment, announced it will release its first quarter 2026 financial results on May 7, 2026, after market close. The company will also host an investor conference call and webcast to discuss the results, providing investors with updated financial performance information and business outlook.

SkinHealth Systems to Report First Quarter 2026 Financial Results on May 7, 2026
SKIN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SkinHealth Systems is set to report its first quarter 2026 financial results on May 7, 2026.
  • The company will hold an investor call and webcast following the release to discuss performance.
  • SkinHealth Systems is a global medical aesthetics company known for Hydrafacial and other skin treatment technologies, impacting the healthcare and consumer wellness sectors.

LONG BEACH, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced it will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. The Company will host an investor conference call at 4:30 p.m. Eastern Time, following a press release detailing the results.

A live webcast of the call can be accessed on the investor relations section of the Company’s website at www.skinhealthsystems.com, along with supporting materials. A recording of the call will become available on the site approximately three hours after its conclusion.

Disclosure Information
SkinHealth Systems announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls and on the investor relations section of its website (www.skinhealthsystems.com) as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About SkinHealth Systems
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp™ with Keravive™, SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide. Learn more at skinhealthsystems.com or follow us on LinkedIn. Local providers can be found at hydrafacial.com/find-a-hydrafacialist.

Investors: IR@skinhealthsystems.com
Press: press@skinhealthsystems.com


Risks

  • Potential variability in financial performance as reflected in quarterly results could impact stock price and investor sentiment.
  • Market competition in the medical aesthetics space could affect future growth and profitability.
  • Regulatory changes or challenges related to medical device approvals and clinical validations could impact operations.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026